1 |
CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03235
D03235
|
Filgrastim
| 35件: 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
2 |
CSF3R
| 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03247
D03247
|
Lenograstim
| 7件: 2 2, 13, 16, 18, 19, 57, 65 |
3 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
4 |
ADRA1D
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
5 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
6 |
ADRA1B
| 6件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
7 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
8 |
ADRA1A
| 7件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D07874
D07874
|
Doxazosin
| 2件: 57 57, 67 |
9 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
10 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
11 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
12 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D00235
D00235
|
Atenolol
| 1件: 167 167 |
13 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
14 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D00378
D00378
|
Timolol
| 2件: 157 157, 227 |
15 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D00432
D00432
|
Nadolol
| 1件: 6 6 |
16 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
17 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D02342
D02342
|
Bisoprolol
| 4件: 58 58, 67, 86, 113 |
18 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
19 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02358
D02358
|
Metoprolol
| 6件: 17 17, 57, 58, 113, 193, 226 |
20 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
21 |
ADRB1
| 11件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03879
D03879
|
Dobutamine
| 4件: 57 57, 58, 86, 215 |
22 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D05127
D05127
|
Nebivolol
| 4件: 17 17, 85, 113, 167 |
23 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D07660
D07660
|
Celiprolol
| 1件: 168 168 |
24 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D07916
D07916
|
Esmolol
| 1件: 58 58 |
25 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
26 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
27 |
ADRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Dilated cardiomyopathy | D08600
D08600
|
Timolol
| 2件: 157 157, 227 |
28 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
29 |
ACE
| 6件: Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D07499
D07499
|
Benazepril
| 4件: 49 49, 57, 218, 224 |
30 |
DMD
| 3件: Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis | D09900
D09900
|
Eteplirsen
| 1件: 113 113 |
31 |
DMD
| 3件: Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis | D10114
D10114
|
Drisapersen
| 1件: 113 113 |
32 |
DMD
| 3件: Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis | D11528
D11528
|
Viltolarsen
| 1件: 113 113 |
33 |
DMD
| 3件: Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis | D11707
D11707
|
Golodirsen
| 1件: 113 113 |
34 |
DMD
| 3件: Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis | D11988
D11988
|
Casimersen
| 1件: 113 113 |
35 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00400
D00400
|
Valsartan
| 7件: 57 57, 58, 66, 75, 218, 222, 224 |
36 |
ITGA4
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D06590
D06590
|
Firategrast
| 1件: 13 13 |
37 |
ITGA4
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D06886
D06886
|
Natalizumab
| 6件: 13 13, 15, 25, 46, 63, 96 |
38 |
ITGA4
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08083
D08083
|
Vedolizumab
| 3件: 94 94, 96, 97 |
39 |
ITGA4
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D10540
D10540
|
Abrilumab
| 2件: 96 96, 97 |
40 |
ITGB7
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08083
D08083
|
Vedolizumab
| 3件: 94 94, 96, 97 |
41 |
ITGB7
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D09901
D09901
|
Etrolizumab
| 2件: 96 96, 97 |
42 |
ITGB7
| 9件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D10540
D10540
|
Abrilumab
| 2件: 96 96, 97 |
43 |
MYH7
| 4件: Thyroid hormone signaling pathway Thyroid hormone signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Viral myocarditis | D12265
D12265
|
Mavacamten
| 1件: 58 58 |
44 |
PPARA
| 10件: PPAR signaling pathway PPAR signaling pathway, cAMP signaling pathway, Adipocytokine signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D01366
D01366
|
Bezafibrate
| 7件: 20 20, 93, 94, 160, 296, 316, 324 |
45 |
CACNA2D3
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
46 |
CACNA2D3
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02716
D02716
|
Pregabalin
| 5件: 13 13, 36, 46, 70, 298 |
47 |
TGFB1
| 25件: MAPK signaling pathway MAPK signaling pathway, FoxO signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Hippo signaling pathway, Th17 cell differentiation, Intestinal immune network for IgA production, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D09620
D09620
|
Fresolimumab
| 3件: 51 51, 85, 222 |
48 |
TGFB2
| 22件: MAPK signaling pathway MAPK signaling pathway, FoxO signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Hippo signaling pathway, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D09620
D09620
|
Fresolimumab
| 3件: 51 51, 85, 222 |
49 |
TGFB3
| 19件: MAPK signaling pathway MAPK signaling pathway, FoxO signaling pathway, TGF-beta signaling pathway, Hippo signaling pathway, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Renal cell carcinoma, Pancreatic cancer, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D09620
D09620
|
Fresolimumab
| 3件: 51 51, 85, 222 |
50 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D00742
D00742
|
Etanercept
| 16件: 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285 |
51 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D00754
D00754
|
Thalidomide
| 20件: 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
52 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
53 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02597
D02597
|
Adalimumab
| 17件: 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 |
54 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02598
D02598
|
Infliximab
| 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
55 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D03441
D03441
|
Certolizumab pegol
| 8件: 37 37, 46, 49, 96, 97, 107, 226, 271 |
56 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D04358
D04358
|
Golimumab
| 8件: 46 46, 56, 84, 96, 97, 107, 270, 271 |
57 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D04687
D04687
|
Lenalidomide
| 8件: 16 16, 26, 28, 34, 49, 284, 300, 331 |
58 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D05393
D05393
|
Pegsunercept
| 1件: 46 46 |
59 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D08976
D08976
|
Pomalidomide
| 5件: 28 28, 51, 85, 227, 331 |
60 |
TNF
| 51件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09944
D09944
|
Ozoralizumab
| 1件: 46 46 |
61 |
XDH
| 6件: Purine metabolism Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome | D00224
D00224
|
Allopurinol
| 7件: 6 6, 46, 57, 60, 66, 96, 97 |
62 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
63 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
64 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
65 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
66 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
67 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
68 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
69 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
70 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
71 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
72 |
CACNA1C
| 20件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
73 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
74 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
75 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
76 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
77 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
78 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
79 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
80 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
81 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
82 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
83 |
CACNA1D
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
84 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
85 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
86 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
87 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
88 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
89 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
90 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
91 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
92 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
93 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
94 |
CACNA1F
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
95 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
96 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
97 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
98 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
99 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
100 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
101 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
102 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
103 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
104 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
105 |
CACNA1S
| 15件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
106 |
CACNA2D1
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
107 |
CACNA2D1
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02716
D02716
|
Pregabalin
| 5件: 13 13, 36, 46, 70, 298 |
108 |
CACNA2D1
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D11203
D11203
|
Mirogabalin
| 1件: 70 70 |
109 |
CACNA2D2
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
110 |
CACNA2D2
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02716
D02716
|
Pregabalin
| 5件: 13 13, 36, 46, 70, 298 |
111 |
CACNA2D2
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D11203
D11203
|
Mirogabalin
| 1件: 70 70 |
112 |
CACNA2D4
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00332
D00332
|
Gabapentin
| 5件: 6 6, 13, 19, 70, 298 |
113 |
CACNA2D4
| 4件: MAPK signaling pathway MAPK signaling pathway, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02716
D02716
|
Pregabalin
| 5件: 13 13, 36, 46, 70, 298 |